Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Risk of leukemia after platinum-based chemotherapy for ovarian cancer.

Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, Curtis RE, Hall P, Andersson M, Pukkala E, Sturgeon J, Stovall M.

N Engl J Med. 1999 Feb 4;340(5):351-7.

2.

Treatment-associated leukemia following testicular cancer.

Travis LB, Andersson M, Gospodarowicz M, van Leeuwen FE, Bergfeldt K, Lynch CF, Curtis RE, Kohler BA, Wiklund T, Storm H, Holowaty E, Hall P, Pukkala E, Sleijfer DT, Clarke EA, Boice JD Jr, Stovall M, Gilbert E.

J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71.

PMID:
10904090
3.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
4.

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.

Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP.

Gynecol Oncol. 2002 Oct;87(1):8-16.

PMID:
12468336
5.

Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.

Dittrich Ch, Sevelda P, Salzer H, Obermair A, Speiser P, Breitenecker G, Schemper M, Kaider A; Austrian Ovarian Cancer Study Group.

Eur J Cancer. 2003 May;39(8):1129-40. Erratum in: Eur J Cancer. 2004 Mar;40(4):627.

PMID:
12736113
7.

Risk of leukemia after chemotherapy and radiation treatment for breast cancer.

Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN.

N Engl J Med. 1992 Jun 25;326(26):1745-51.

8.

A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study.

Benedetti Panici P, Greggi S, Amoroso M, Scambia G, Battaglia FA, Gebbia V, Salerno G, Paratore MP, Mancuso S.

Int J Gynecol Cancer. 2001 Nov-Dec;11(6):438-44.

PMID:
11906546
9.

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.

Brusamolino E, Anselmo AP, Klersy C, Santoro M, Orlandi E, Pagnucco G, Lunghi F, Maurizi-Enrici R, Baroni CD, Lazzarino M, Mandelli F, Bernasconi C.

Haematologica. 1998 Sep;83(9):812-23.

10.

Leukemia following chemotherapy for ovarian cancer.

Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, Mehnert W, Bell J, Høst H, Prior P, Karjalainen S, et al.

N Engl J Med. 1990 Jan 4;322(1):1-6.

11.

High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.

Fanning J, Hilgers RD.

Gynecol Oncol. 1993 Nov;51(2):182-6.

PMID:
8276291
13.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
14.

Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.

Hensley ML, Lebeau D, Leon LF, Venkatraman E, Waltzman R, Sabbatini P, Almadrones L, Chi D, Spriggs D.

Gynecol Oncol. 2001 Jun;81(3):485-9.

PMID:
11371143
15.

Risk of leukemia following treatment for non-Hodgkin's lymphoma.

Travis LB, Curtis RE, Stovall M, Holowaty EJ, van Leeuwen FE, Glimelius B, Lynch CF, Hagenbeek A, Li CY, Banks PM, et al.

J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7.

PMID:
8089863
16.

Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.

Pujade-Lauraine E, Guastalla JP, Weber B, Curé H, Orfeuvre H, Mousseau M, Vincent P, Diéras V, Tubiana-Mathieu N, Jacquin JP, Mignot L, Leduc B, Paraïso D, Viens P.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-30-S15-35.

PMID:
9346219
17.

Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.

Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E.

J Natl Cancer Inst. 2002 Feb 6;94(3):182-92.

PMID:
11830608
18.

Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.

Thigpen T, Vance R, Puneky L, Khansur T.

Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97-107. Review.

PMID:
7835816
19.

Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.

du Bois A, Lück HJ, Meier W, Möbus V, Costa S, Richter B, Bauknecht T, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C.

Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-28-S11-33.

PMID:
9314296
20.

Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment.

Le T, Leis A, Pahwa P, Wright K, Ali K, Reeder B, Hopkins L, Fung MF.

Gynecol Oncol. 2004 Mar;92(3):839-44.

PMID:
14984950

Supplemental Content

Support Center